CD28-negative CD8-positive Cytotoxic T Lymphocytes Mediate Hepatocellular Damage in Hepatitis C Virus Infection

Journal of Clinical Immunology

Volumn 23, Issue 6, 2003, Pages 518-527

  Kurokohchi, Kazutaka ^a   Masaki, Tsutomu ^a   Arima, Keiji ^a   Miyauchi, Yoshiaki ^a   Funaki, Toshiharu ^a   Yoneyama, Hirohito ^a   Yoshida, Shuhei ^a   Deguchi, Akihiro ^a   Nakai, Seiji ^a   Watanabe, Seishiro ^a   Kuriyama, Shigeki ^a  

^a KAGAWA UNIVERSITY   (Japan)

Author keywords

CD28 molecule; Costimulatory molecule; FACS; HCV (hepatitis C virus); Immunology; Lymphocytes

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIBODY; B7 ANTIGEN; CD28 ANTIBODY; CD28 ANTIGEN; CD40 LIGAND; CD8 ANTIGEN; HLA A24 ANTIGEN; OKT 4; OKT 8; UNCLASSIFIED DRUG;

ANALYSIS; ANTIGEN BINDING; ARTICLE; BIOACCUMULATION; CELL INFILTRATION; CELL ISOLATION; CELL STIMULATION; CHRONIC ACTIVE HEPATITIS; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; FLOW CYTOMETRY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LIVER CELL DAMAGE; MAJOR CLINICAL STUDY; MALE; MOLECULE; MONONUCLEAR CELL; PATIENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; STIMULATION;

ANTIGENS, CD28; ANTIGENS, CD8; CD8-POSITIVE T-LYMPHOCYTES; FLOW CYTOMETRY; HEPATITIS C; HLA-A ANTIGENS; HUMANS; LIVER; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES, CYTOTOXIC;

EID: 10744229975     PISSN: 02719142     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:JOCI.0000010428.98823.02     Document Type: Article

References (55)

1. Cerny A, Ferrari C, Chisari FV: The class I-restricted cytotoxic T lymphocyte response to predetermined epitopes in the hepatitis B and C viruses. Curr Top Microbiol Immunol 189:169-186, 1994
2. Koziel MJ, Dudley D, Wong JT, Dienstag J, Houghton M, Ralston R, Walker BD: Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis. J Immunol 149:3339-3344, 1992
3. Koziel MJ, Dudley D, Afdhal N, Choo Q, Houghton M, Ralston R, Walker BD: Hepatitis C virus (HCV)-specific cytotoxic T lymphocytes recognize epitopes in the core and envelope proteins of HCV. J Virol 67:7522-7532, 1993
4. Koziel MJ, Dudley D, Afdhal N, Grakoui A, Rice CM, Choo QL, Houghton M, Walker BD: HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus. Identification of multiple epitopes and characterization of patterns of cytokine release. J Clin Invest 96:2311-2321, 1995
5. Nelson DR, Marousis CG, Davis GL, Rice CM, Wong J, Houghton M, Lau JYN: The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C. J Immunol 158:1473-1481, 1997
6. Battegay M, Fikes J, Di-Bisceglie AM, Wentworth PA, Sette A, Celis E, Ching WM, Grakoui A, Rice CM, Kurokohchi K, Berzofsky JA, Hoofnagle JH, Feinstone SM, Akatsuka T: Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2.1 molecules. J Virol 69:2462-2470, 1995
7. Kaneko T, Nakamura I, Kita H, Hiroishi K, Moriyama T, Imawari M: Three new cytotoxic T cell epitopes identified within the hepatitis C virus nucleoprotein. J Gen Virol 77:1305-1309, 1996
8. Kurokohchi K, Akatsuka T, Pendleton CD, Takamizawa A, Nishioka M, Battegay M, Feinstone SM, Berzofsky JA: Use of recombinant protein to identify a motif-negative human cytotoxic T-cell epitope presented by HLA-A2 in the hepatitis C virus NS3 region. J Virol 70:232-240, 1996
9. Freni MA, Artuso D, Gerken G, Spanti C, Marafioti T, Alessi N, Spadaro A, Ajello A, Ferrau O: Focal lymphocytic aggregates in chronic hepatitis C: Occurrence, immunohistochemical characterization, and relation to markers of autoimmunity. Hepatology 22:389-394, 1995
10. Hino K, Okuda M, Konishi T, Yamashita A, Kayano K, Kubota M, Yasunaga M, Fukumoto Y, Okita K: Analysis of lymphoid follicles in liver of patients with chronic hepatitis C. Liver 12:387-391, 1992
11. Parham P: Transporters of delight. Nature 348:674-675, 1990
12. Monaco JJ, Cho S, Attaya M: Transport protein genes in the murine MHC: Possible implications for antigen processing. Science 250:1723-1726, 1990
13. Ortmann B, Androlewicz MJ, Cresswell P: MHC class I/beta 2-microglobulin complexes associate with TAP transporters before peptide binding. Nature 368:864-867, 1994
14. Suh WK, Cohen-Doyle MF, Fruh K, Wang K, Peterson PA, Williams DB: Interaction of MHC class I molecules with the transporter associated with antigen processing. Science 264:1322-1326, 1994.
15. Rosenthal AS: Determinant selection and macrophage function in genetic control of the immune response. Immunol Rev 40:136-152, 1978
16. Schwartz RH: T-lymphocyte recognition of antigen in association with gene products of the major histocompatibility complex. Annu Rev Immunol 3:237-261, 1985
17. Zinkernagel RM, Doherty PC: MHC-restricted cytotoxic T cells: Studies on the biological role of polymorphic major transplantation antigens determining T-cell restriction-specificity, function and responsiveness. Adv Immunol 27:51-177, 1979
18. Townsend A, Bodmer H: Antigen recognition by class I-restricted T lymphocytes. Annu Rev Immunol 7:601-624, 1989
19. Boussiotis VA, Freeman GJ, Gribben JG, Nadler LM: The role of B7-1/B7-2:CD28/CTLA-4 pathways in the prevention of anergy, induction of productive immunity, and down-regulation of the immune response. Immunol Rev 153:47, 1996
20. Schwartz RH: Costimulation of T lymphocytes: The role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 71:1065-1068, 1992
21. Schwartz RH: A cell culture model for T lymphocyte clonal anergy. Science 248:1349-1356, 1990
22. Kurokohchi K, Arima K, Nishioka M: A novel cytotoxic T-cell epitope presented by HLA-A24 molecule in hepatitis C virus infection. J Hepatol 34:930-935, 2001
23. Lichtenfels R, Biddison WE, Schulz H, Vogt AB, Martin R: CARELASWS (calcein-release-assay), an improved fluorescence-based test system to measure cytotoxic T lymphocyte activity. J Immunol Methods 172:227-239, 1994
24. Urdea MS, Horn T, Fultz TJ, Anderson M, Running JA, Hamren S, Ahle D, Chang CA: Branched DNA amplification multimers for the sensitive, direct detection of human hepatitis viruses. Nucleic Acids Symp Ser 24:197-200, 1991
25. Minutello MA, Pileri P, Unutmaz D, Censini S, Kuo G, Houghton M, Brunetto MR, Bonino F, Abrignani S: Compartmentalization of T lymphocytes to the site of disease: Intrahepatic CD4+ T cells specific for the protein NS4 of hepatitis C virus in patients with chronic hepatitis C. J Exp Med 178:17-25, 1993
26. Botarelli P, Brunetto MR, Minutello MA, Calvo P, Unutmaz D, Weiner AJ, Choo QL, Shuster JR, Kuo G, Bonino F, et al.: T-lymphocyte response to hepatitis C virus in different clinical courses of infection. Gastroenterology 104:580-587, 1993
27. Mochizuki K, Hayashi N, Katayama K, Hiramatsu N, Kanto T, Mita E, Tatsumi T, Kazushita N, Kasahara A, Fusamoto H, Yokochi T, Kamada T: B7/BB-1 expression and hepatitis activity in liver tissues of patients with chronic hepatitis C. Hepatology 25:713-718, 1997
28. Tatsumi T, Takehara T, Katayama K, Mochizuki K, Yamamoto M, Kanto T, Sasaki Y, Kasahara A, Hayashi N: Expression of costimulatory molecules B7-1(CD80) and B7-2(CD86) on human hepatocellular carcinoma. Hepatology 25:1108-1114, 1997
29. Tsuneyama K, Water JV, Leung PSC, Cha S, Nakanuma Y, Kaplan M, Lellis RD, Coppel R, Ansari A, Gershwin ME: Abnormal expression of the E2 component of the pyruvate dehydrogenase complex on the luminal surface of biliary epithelium occurs before major hisotocompatibility complex class II and BB1/B7 expression. Hepatology 21:1031-1037, 1995
30. Onji M, Kikuchi T, Kumon I, Masumoto T, Nadano S, Kajino K, Horiike N, Ohta Y: Intrahepatic lymphocyte subpopulations and HLA class I antigen expression by hepatocytes in chronic hepatitis C. Hepatogastroenterology 39:340-343, 1992
31. Liaw YF, Lee CS, Tsai SL, Liaw BW, Chen TC, Sheen IS, Chu CM: T cell mediated autologous hepatocytotoxicity in patients with chronic hepatitis C virus infection. Hepatology 22:1368-1378, 1995.
32. Mosnier JF, Degott C, Marcellin P, Henin D, Erlinger S, Benhamou JP: The intraportal lymphoid nodule and its environment in chronic active hepatitis C: An immunohistochemical study. Hepatology 17:366-371, 1993
33. Turka LA, Ledbetter JA, Lee K, June CH, Thompson CB: CD28 is an inducible T cell surface antigen that transduces a proliferative signal in CD3+ mature thymocytes. J Immunol 144:1646-1653, 1990
34. Laknzavecchia A: Licence to kill. Nature 393:413-414, 1998
35. Krummel MF, Health WR, Allison J: Differential coupling of second signals for cytotoxicity and proliferation in CD8+ T cells effectors: Amplification of the lytic potential by B7. J Immunol 163:2999-3006, 1999
36. Hamann D, Baars PA, Rep MHG, Hooibrink B, Kerkhof-Grade SR, Klein MR, van Lier RAW: Phenotypic and functional separation of memory and effector human CD8+ T cells. J Exp Med 186:1407-1418, 1997
37. Azuma M, Phillips JH, Lanier LL: CD28-T lymphocytes. J Immunol 150:1147-1159, 1993
38. Weekes MP, Carmichael AJ, Wills MR, Mynard K, Sissons JGP: Human CD28-CD8+ T cells contain greatly expanded functional virus-specific memory CTL clones. J Immunol 162:7569-7577, 1999.
39. Posnett DN, Edinger JW, Manavaian JS, Irwin C, Marodon G: Differentiation of human CD8 T cells: Implications for in vivo persistence of CD8+CD28-cytotoxic effector clones. Int Immunol 11:229-241, 1999
40. Scognamiglio P, Accapezzato D, Casciaro MA, Cacciani A, Artini M, Bruno G, Chircu ML, Sidney J, Southwood S, Abrignami S, Sette A, Barnaba V: Presence of effector CD8+ T cells in hepatitis C virus-exposed healthy seronegative donors. J Immunol 162:6681-6689, 1999
41. Dalod M, Sinet M, Deschemin J-C, Florentine S, Venet A, Guillet J-G: Altered ex vivo balance between CD28+ and CD28-cells within HIV-specific CD8+ T cells of HIV-seropositive patients. Eur J Immunol 29:38-44, 1999
42. Appay V, Dunbar PR, Callan M, Klenerman P, Gillespie GMA, Papagno L, Ogg GS, King A, Lechner F, Spina CA, Little S, Havlir DV, Richman DD, Gruener N, Pape G, Waters A, Easterbrook P, Salio M, Cerundolo V, McMichael AJ, Rowland-Jones S: Memory CD8+ T cells vary in diffentiation phenotype in different persistent virus infection. Nat Med 8:379-385, 2002
43. Nagata S, Goldstein P: The Fas death factor. Science 267:1449-1456, 1995
44. Kunitani H, Shimizu Y, Murata H, Higuchi K, Watanabe A: Phenotypic analysis of circulating and intrahepatic dendritic cell subsets in patients with chronic liver disease. J Hepatol 36:734-741, 2002
45. Sobao Y, Tomiyama H, Nakamura S, Sekihara H, Tanaka K, Takiguchi M: Visual demonstration of hepatitis C virus-specific memory CD8(+) T-cell expansion in patients with acute hepatitis C. Hepatology 33:287-294, 2001
46. Ibe M, Sakaguchi T, Tanaka K, Saito S, Yokota S, Tanaka T, Shimotohno K, Chujoh Y, Shiratori Y, Omata M, Miwa K, Takiguchi M. Identification and characterization of a cytotoxic T cell epitope of hepatitis C virus presented by HLA-B3501 in acute hepatitis. J Gen Virol 79:1735-1744, 1998
47. Di-Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, Goodman Z, Banks SM, Hoofnagle JH: Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 321:1506-1510, 1989
48. Di-Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Goodman Z, Banks SM, Hoofnagle JH: A randomized, double-blind, placebo-controlled trial of recombinant human alpha-interferon therapy for chronic non-A, non-B (type C) hepatitis. J Hepatol 11:601-603, 1990
49. Shindo M, Di-Bisceglie AM, Hoofnagle JH: Long-term follow-up of patients with chronic hepatitis C treated with alpha-interferon. Hepatology 15:1013-1016, 1992
50. Kiefersauer S, Reiter C, Eisenburg J, Diepolder HM, Rieber EP, Riethmuller G, Gruber R: Depletion of CD8+ T lymphocytes by murine monoclonal CD8 antibodies and restored specific T cell proliferation in vivo in a patient with chronic hepatitis C. J Immunol 159:4064-4071, 1997
51. Najafian N, Sayegh MH: CTLA4-Ig: A novel immunosuppressive agent Expert Opin Investig Drugs 9:2147-2157, 2000
52. Kurlberg G, Haglind E, Schon K, Tornqvist H, Lycke N: Blockade of the B7-CD28 pathway by CTLA4-Ig counteracts rejection and prolongs survival in small bowel transplantation. Scand J Immunol 51:224-230, 2000
53. Deurloo DT, van Esch BC, Hofstra CL, Nijkamp FP, van Oosterhout AJ: CTLA4-IgG reverses asthma manifestations in a mild but not in a more "severe" ongoing murine model. Am J Respir Cell Mol Biol 25:751-760, 2001
54. Dong VM, Yuan X, Colto AJ, Waaga AM, Sayegh MH, Chandraker A: Mechanisms of targeting CD28 by a signaling monoclonal antibody in acute and chronic allograft rejection. Transplantation 27: 1310-1317, 2002
55. Comer RM, King WJ, Ardjomand N, Theoharis S, George AJ, Larkin DF: Effect of administration of CTLA4-Ig as protein or cDNA on corneal allograft survival. Invest Ophtalmol Vis Sci 43:1095-1103, 2002